Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258259 | 0.87 | DRD2 (0.60) | USP2HTTDRD2DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL4253960 | 0.86 | DRD2 (0.60) | USP2HTTDRD2DRD3HTR1A | |
| SCHEMBL4253491 | 0.82 | HTT (0.66) | USP2HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4253499 | 0.81 | DRD2 (0.61) | DRD2DRD3HTR1AHTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL4257351 | 0.81 | DRD2 (0.61) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL4261632 | 0.79 | DRD2 (0.59) | MEN1MAPTKMT2ATDP1DRD2 | |
| Hydrochloric Acid SCHEMBL4255247 | 0.79 | DRD2 (0.58) | MEN1MAPTKMT2ATDP1DRD2 | |
| SCHEMBL13099992 | 0.76 | HTT (0.73) | USP2HTTMAPTTSHRKMT2A | |
| SCHEMBL4258732 | 0.75 | USP2 (0.53) | USP2HTTMEN1MAPTTSHR | |
| SCHEMBL4256238 | 0.75 | HTT (0.72) | USP2HTTMEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | USP2 3572/4885HTT 1182/4885MEN1 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.